Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,798 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. Among authors: ogura y. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
IgG4-related lung disease progressing to respiratory failure.
Kunimatsu Y, Tani N, Sato I, Ogura Y, Hirose K, Takeda T. Kunimatsu Y, et al. Among authors: ogura y. Respirol Case Rep. 2020 Aug 11;8(7):e00641. doi: 10.1002/rcr2.641. eCollection 2020 Oct. Respirol Case Rep. 2020. PMID: 32789018 Free PMC article.
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Morimoto K, Yamada T, Nakamura R, Katayama Y, Tanaka S, Takumi C, Hiraoka N, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: ogura y. Med Oncol. 2020 Nov 11;37(12):111. doi: 10.1007/s12032-020-01440-3. Med Oncol. 2020. PMID: 33175248
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
Morimoto K, Yamada T, Takumi C, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: ogura y. Front Oncol. 2021 Mar 23;11:630136. doi: 10.3389/fonc.2021.630136. eCollection 2021. Front Oncol. 2021. PMID: 33833990 Free PMC article.
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.
Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K. Tanimura K, et al. Among authors: ogura y. NPJ Precis Oncol. 2022 Jan 18;6(1):5. doi: 10.1038/s41698-021-00250-8. NPJ Precis Oncol. 2022. PMID: 35042943 Free PMC article.
1,798 results